C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia.
The usefulness of determining serum levels of C-reactive protein (CRP) for the identification of bacterial infections in febrile neutropenic patients with cancer was evaluated. Two hundred children with cancer were monitored prospectively for the occurrence of neutropenia and fever; serum was collected from these children for determining baseline levels of CRP. Of these 200 children, 75 had 85 febrile neutropenic episodes; serum was collected daily from these 75 children for CRP analysis by nephelometry. Children were included into one of the three following groups by physicians blinded to results of CRP analysis: group I, demonstrated bacterial infection (24 episodes); group II, probable bacterial infection (31 episodes); and group III, viral infection or no infection (30 episodes). Baseline CRP values were low (mean, 9 mg/L; range, 0-35 mg/L) irrespective of tumor type or stage of therapy. Mean CRP values on day 1 for children in groups I and II (194 and 143 mg/L, respectively) were higher than those for children in group III (29 mg/L) (P < .001). A CRP value of > 40 mg/L discriminated children with a demonstrated bacterial infection (sensitivity, 100%; specificity, 76.6%). Children with an unfavorable outcome had persistently high levels of serum CRP. For children with cancer, neutropenia, and fever, determination of the serum CRP level is useful for early diagnosis of bacterial infections and for monitoring the course of infection.
Santolaya
M E
ME
Division of Infectious Diseases and Oncology, Luis Calvo Mackenna Hospital, Santiago, Chile.
Cofre
J
J
Beresi
V
V
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000097:blood / Q000150:complications / Q000175:diagnosis; D002097:C-Reactive Protein / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000097:blood* / Q000150:complications*; D009503:Neutropenia / Q000097:blood / Q000150:complications; D011446:Prospective Studies
D000900:Anti-Bacterial Agents; D002097:C-Reactive Protein